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Sickle cell disease (SCD) is a genetic blood disorder that causes the red blood cells 
(RBC) to become sickle shaped due to a mutation in the β-globin gene encoding the 
protein hemoglobin. This disease causes reduced oxygen carrying capacity of RBC 
resulting in painful crisis, vasculopathy, infarction, hemolytic anemia, and infection 
susceptibility. SCD affects around 100,000 individuals in USA alone and 14 million 
people globally. SCD affected individuals have high mortality rates. Early detection 
and constant monitoring of this disease is essential. The following review focuses on 
various methodologies that have emerged in the diagnosis of SCD. Also, low cost 
methods that can be easily adopted in developing nations are discussed. Various 
conventional screening techniques and emerging Point-of-care (POC) methodologies 
for detection of SCD are covered in this review. The advantages and limitations of these 
techniques are discussed. Some of the popular conventional techniques explained here 
in details include the following: hemoglobin electrophoresis, isoelectric focusing (IEF), 
high performance liquid chromatography (HPLC), liquid chromatography-mass 
spectrometry (LC-MS) and deoxyribonucleic acid (DNA) analysis. Under DNA 
analysis there are again several methodologies, that include use of restriction enzyme 
along with polymerase chain reaction (PCR) to detect mutation in the SCD individuals; 
exome sequencing of DNA and direct genotyping for the single-nucleotide 
polymorphism (SNP) that encodes the sickle mutation and also genome-wide 
association studies (GWAS) used to detect SCD. The emerging POC technologies for 
SCD screening have also been covered here that include the following methodologies; 
paper-based hemoglobin solubility assays, Lateral Flow Immunoassays, Density-based 
separation methods and Micro engineered electrophoresis. The goal of this review is to 
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Sickle cell disease (SCD) is caused by a single nucleotide substitution (GAG to GTG) 
due to a point mutation in the β-globin gene, which results in a substitution change 
replacing amino acid glutamic acid with valine at the sixth position of the beta globin 
chain thus resulting in the production of the sickle hemoglobin (HbS) (Randolph et al. 
2012). Individuals having both the β-globin gene allele mutated are called homozygous 
(HbSS) and show various symptoms of SCD whereas those with a single mutated β-
globin gene are known as sickle cell trait (HbSA) or carriers and are asymptomatic. The 
oxyhemoglobin dissociation curve is right shifted in SCD patients indicating a lower 
affinity of the sickle hemoglobin for oxygen (Abdu et al. 2008). Reduced oxygen 
tension causes polymerization of this mutated form of hemoglobin, thus changing the 
shape of the red blood cells (RBC) to a sickle shape, which thereby results in 
development of chronic anemia, acute painful crisis that arises due to blockage of small 
vessels. Progressive damage to multiple organs sets in over time that includes damage 
to brain, kidneys, lungs, bones and cardiovascular system (Rees et al. 2010). 
Around 14 million individuals are affected by SCD worldwide, where as in the United 
States alone 80,000-100,000 people primarily African Americans have this disease 
(Brousseau et al. 2010; Alapan et al. 2016). Annually, the overall healthcare cost of 
SCD in US alone is estimated to be over $1 billion. (Ballas et al. 2009). 
Like any hereditary disease, attempts to prevent its occurrence are the best approaches 
against SCD. The first level of prevention is known as prenatal diagnosis (PND), which 
makes parents who are homozygous for SCD be aware of the risk of having a child with 
SCD. People living in the remote areas and in developing nations are not aware of the 
risk of having a child born with SCD due to the lack of information and appropriate 
diagnostic tools.  
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Also, the second level of prevention is neonatal screening. Mortality due to infection 
and stroke is very common in newborns that are not diagnosed for SCD, which happens 
when newborns are not screened for the presence of sickle hemoglobin in the blood. 
Studies have shown that there is a greater risk of Streptococcus pneumonia infection in 
children up to 3 years of age. The mortality rate in these children is as high as 30% 
(Yanni et al. 2009). Hence, it is essential to carry out neonatal screening for SCD so 
that proper management can be delivered to reduce newborn mortality rates. This 
problem is acute in developing countries where early diagnosis is not very prevalent 
and hence a relatively higher number of newborn mortality due to sickle cell disease is 
observed in these nations.  
Developed nations rely on molecular and protein-based tests to diagnose SCD. 
Molecular tests are expensive and thus not a practical approach in underdeveloped 
countries. In African countries for instance, screening attempts have been unsuccessful 
mostly due to the high cost of screening kits available in the market (Hajer et al. 2012). 
In addition to the cost issue, other challenges faced by healthcare professional include 
the heterogeneities among SCD patients and the multiple organs effected in this disease.  
This review describes various SCD screening and monitoring methodologies. It also 
discusses the challenges involved with such technologies and future of SCD screening. 
The review also describes low cost techniques that can be implemented in developing 




2. Various methodologies for SCD Diagnosis 
 
2.1 Conventional methodologies 
RBCs of affected individuals have varying percentages and combinations of HbS, HbA, 
HbF, HbC, and HbA2. Patients are diagnosed and categorized as belonging to 
homozygous HbSS (sickle cell anemia, SCA) and heterozygous HbSA (sickle cell trait, 
SCT), HbSC disease and HbS-β thalassemias based upon the percentages and 
combinations of the above-mentioned types of hemoglobin. The sickling test and the 
sickle solubility test are two of the basic tests that are popularly used to detect the sickle 
hemoglobin in the blood sample (Berg, A. O. 1994).  
In the sickling test, polymerization of sickle hemoglobin is induced by sodium 
metabisulfite followed by sickling of the RBC by reducing oxygen tension. 
Microscopic analysis is conducted by taking a sample of this diluted blood and observed 
for the presence of sickled RBC. The test is very simple to carry but the major drawback 
of the test is it cannot differentiate between different forms of hemoglobin that include 
HbSS, HbSA, HbSC, or HbS- β thalassemias. The test requires an incubation time 
between 1-4 hours. after which the slide is examined under a microscope. Sickling test 
is performed for routine health screenings or if a disease or toxicity is suspected. 
In the solubility test, a concentrated buffer solution made of phosphate is used to reduce 
HbS into an insoluble state. Precipitation of HbS thus occurs in reduced state to form 
tactoids, which makes the solution turbid. A positive and negative control blood sample 
is used to compare the light refraction (Diggs et al. 1975). The biggest drawback of this 
test is, newborns predominantly have HbF in their blood and do not have much of HbSS 
(SCA) or HbSA (SCT) to give rise to considerable amount of HbS, which this test 
detects. Hence lot of times although a newborn is homozygous for sickle hemoglobin 
may end up giving false-negative result in this test. This phenomenon is generally 
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observed when the HbS concentration in the newborn is less than 10% of the total 
hemoglobin.  
This test is not considered as an optimal test to differentiate between SCD from SCT 
because it has the potential to cause confusion between them. Also, other tests, that can 
positively identify the homozygote from heterozygote are available (Tubman et al. 
2015). Other clinically significant forms of sickle hemoglobinopathies that include 
HbC and β-thalassemia cannot be detected in this test (Fabry et al. 2003).  
In order to determine the type of hemoglobin present, (SCA vs SCT), additional tests 
need to be carried out, which include the following: hemoglobin electrophoresis, high 
performance liquid chromatography (HPLC), isoelectric focusing (IEF), and DNA 
based analysis (Greene et al. 2015). The basic principle upon which electrophoresis-
based techniques operate is that different types of hemoglobin molecules carry different 
charges on them and hence they migrate at different velocities in an electrophoresis gel 
when an electric current is applied. Each of the above mentioned are explained in detail 
below.  
2.12 Hemoglobin electrophoresis: 
Unaffected individual has the following proportions of hemoglobins - HbA= >95%; 
(95-98%); HbA2 = 1.5-3.7%; HbF=<2%;( 0.8-2%); HbS =0%; HbC =0% and Newborn 
HbF = 50-80%. Hemoglobin electrophoresis is a method used to discriminate between 
these different types of hemoglobin under alkaline conditions using variety of sieving 
materials that includes gel and paper. Under alkaline condition various forms of 
hemoglobin have a net negative charge and move towards the positive electrode. 
Different hemoglobin form migrates to different lengths on the gel based on the charge 
carried by these molecules, pore size of the medium and the ionic strength of the buffer 
solution. A condition can be determined based on the various bands observed on the 
gel. The advantage of this methodology is rapid screening of small number of samples 
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is possible. After electrophoretic separation, densitometry is used to quantify various 
forms of hemoglobin observed on the gel. However, at low sample concentration 
densitometry suffer from inaccuracy of result. The resolution between HbF and HbS is 
very low and hard to distinguish in neonates having high concentration of HbF.  
For high-throughput screening a capillary zone electrophoresis (CZE) is carried out in 
a U-shaped narrow-bore fused-silica capillary tube. Like HPLC, CZE is an automated 
method and has been shown in various studies to be an effective methodology to detect 
monoclonal gammopathies and protein abnormalities present in the serum. Migration 
in CZE is similar to conventional electrophoretic methods in which the protein migrates 
based on its net charge when an electric field in applied. The buffers used in CZE differ 
from gel electrophoresis where barbital buffer is used. Barbital buffer has a 
disadvantage since it has a high absorbance at 200nm wavelength, which coincides with 
peptide bonds and thus interferes with the detection system. To avoid this CZE uses 
borate-based buffers that do not cause the above interference (Dolník et al. 1995).  
The negative charge of the fused silica used to make the capillaries provides a negative 
surface charge to the migrating protein molecules. Also, the narrow lumen (about 50μm 
in diameter) inside the capillary tubes makes the surface area relatively large. This 
combined effect of large surface area and charge on the capillaries causes a more 
effective movement of proteins in the sample towards the cathode than could have been 
achieved by only voltage difference between cathode and anode. This high charge and 
surface area offered by the capillaries causes a higher resolution of the hemoglobin 
variants present in the samples.  A detector is usually present at the cathodal end of the 
capillary, which records the optical density at a wavelength of 200nm (peptide bond 
absorption) as the proteins migrate past it. The Hb variants pass by the detector in the 
following order-γ, β, α2, and α1 globulins (Keren et al. 1998). 
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High resolution, ease of automation, shorter run time at a high voltage and no additional 
requirement for densitometer are the advantages of the CZE methodology for diagnosis 
of SCD. However, CZE is a new technology and the limitations haven’t been properly 
investigated so far. One major drawback is this methodology does not have any gel that 
can be examined. The bands represent those substances that have absorbency at around 
200 nm, which are usually proteins. Non-protein substances having similar absorbency 
parameters can therefore also produce bands that can be confused with hemoglobin 
variants (Keren et al. 1998; Bain, B. J. 2008). CZE requires a detector, which records 
optical density at a wavelength of 200nm and this is connected to a computer for data 
acquisition and also needs high voltage power supply. All these arrangements are 
expensive and are not readily available in remote areas hence CZE-based SCD 
screening methodology is not easy to implement in developing or in underdeveloped 
countries.  
2.13 Isoelectric focusing (IEF): 
Every protein carries a net charge that varies according to the pH of the surrounding 
environment. An isoelectric point (pI) is defined as a point in pH gradient where a 
protein carries a net zero charge. Hemoglobin samples are run in a gel medium across 
which an electrical gradient is applied, and a fixed pH gradient is maintained throughout 
the gel (Fig. 1). Different types of hemoglobins present in the blood sample travel and 
stop at the location in the gel at their respective pI. Resolution of IEF is better than Hb 
electrophoresis and thus this technique is useful in distinguishing between higher 
populations of individuals with variant Hb (Bain, B. J. 2008). The disadvantage of this 
technique is that the interpretation of result sometimes becomes difficult due to the 
presence of a higher number of bands on the gel. Also, the technique is more expensive 
compared to Hb electrophoresis method. Like Hb electrophoresis, the quantitation 
depends on densitometric analysis, that sometimes gives inaccurate interpretation. 
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However, IEF is the method of choice for screening newborns in many clinical settings 
since this methodology can operate at a very small volume and even gives reliable 
results from dried blood spot samples (World Health Organization 2006; APLH & CDC 
- Hemoglobinopathies -Current Practices for Screening, Confirmation and Follow-up -
DECEMBER 2015).  
In a pilot study conducted in Tunisia, a low cost neonatal screening method using IEF 
assay for the detection of SCD and other Hb variants has been reported (Hajer et al. 
2012). In this study samples from 9148 newborns were collected on blotting paper 
(Whatman grade BFC 180) at maternity centers and using a general office-use printer 
these blotting papers were printed. IEF methodology was then carried out by a lab-
prepared agarose gel to test the dried blood samples from these newborns. This low cost 
IEF on lab prepared agarose gel along with office printer printed blotting paper for 
sample collection proved to be an effective method since this method successfully 
detected the newborns who had abnormal Hbs (HbS, HbC, HbO and HbG). The 
accuracy of the data collected in this screening method was also verified by comparing 
with previously established national data. The families of these newborns were made 




Figure 1 Isoelectric focusing (IEF): The illustration showing the various steps in IEF (APLH & CDC - 
Hemoglobinopathies -Current Practices for Screening, Confirmation and Follow-up -DECEMBER 2015). 
 
2.14 High Performance Liquid Chromatography (HPLC): 
Cation exchange HPLC uses charge to separate different types of hemoglobin in the 
blood. HPLC has a negatively charged stationary phase comprising of an absorbent 
material that can be either silica or other polymers. The mobile phase is a liquid with 
an increasing concentration of cations that passes through the chromatography column. 
A pressure pump is used to drive the fluid through the chromatography column. The 
HPLC is connected to the computer, which shows separation of the various hemoglobin 
types on a screen. HPLC offers the advantages such as full automation of the entire 
procedure and accurate quantification of the levels of hemoglobin present as long a 
variant or known Hb in the patient sample does not interfere with the interpretation 
(Greene et al. 2015). The disadvantage of HPLC technique is the cost of the instrument 
that makes this technique not practical to operate in developing countries for screening 
of population for SCD. In developed countries like the US, HPLC is the methodology 
of choice for primary screening of SCD individuals over Hb electrophoresis and IEF 
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(Alapan et al .2016). HPLC is much less labor intensive, accurate and less time-
consuming method in comparison to the Hb electrophoresis. HPLC can also be used on 
SCD individuals on hydroxyurea (HU) or transfusion therapies (Makani et al. 2013). 
HU is the drug-of-choice to reduce the pain episode frequency in sickle cell patients. 
HU raises the level of HbF that significantly decreases the rate of painful episodes by 
about 50% (Agrawal et al. 2014). Blood transfusion lowers the amount of sickle 
hemoglobin in the body. Since the normal red blood cells increase in the blood stream 
thus increasing the supply of oxygen. 
2.15 Liquid Chromatography-Mass spectrometry (LC-MS/MS): 
It is important to also include liquid chromatography-mass spectrometry (LC-
MS/MS) (also known as tandem mass spectrometry) under this category since it is a 
much faster and accurate and can be used for cost effective population of screening of 
sickle cell disease (Chace et al. 2003). For characterization of hemoglobinopathies 
Electrospray ionization in conjunction with tandem MS have been used. Masses of 
intact globin chains can be measured by scanning whole blood. This is followed by 
tryptic digestion of the blood specimen for detailed peptide analysis in order to 
specify the hemoglobin variant in the blood.  This method allows unambiguous 
characterization of majority of globin mutations (Daniel et al. 2005).  
2.16 DNA Analysis: 
DNA based assays can be used to screen patients by looking for mutations in the β-
globin gene that results in the production of the sickle hemoglobin (Clark et al. 2004). 
Compared to the methodologies discussed earlier, DNA analysis to screen SCD is 
usually more expensive. There are two ways DNA analysis can be performed. One 
popular method, known as Restriction Fragment Length Polymorphism (RFLP), looks 
for Ddel I restriction enzyme site in the β-globin gene. Mutation that causes SCD 
eliminates this restriction site. Thus, normal DNA without sickle mutation will be cut 
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with Ddel I whereas DNA having mutation for SCD will not be cut with this enzyme. 
To carry out this procedure first DNA sample from individuals are collected and a 125 
bp region of the β-globin gene is PCR amplified using gene-specific primers and this 
amplified DNA is then subjected to digestion by Ddel I. After incubation with the 
restriction enzyme for a certain time, an aliquot of this reaction is loaded in a gel and 
electrophoresis is carried out. Individuals with mutation in the β-globin gene will have 
one big fragment (125 bp) whereas normal DNA will be cut into two fragments by the 
restriction enzyme (106 bp and 19 bp). It is hard to visualize 19 bp fragment since it’s 
too small to visualize on a gel.  If the individual is homozygous that is both the alleles 
have the S mutation (SS), then only the 125 bp fragment is seen in the gel. Whereas in 
case of sickle cell carriers (Trait) who have both the A and S allele (AS), both the 125 
bp and 106 bp bands are seen. 
RFLP is easy to perform and analyze and is an inexpensive method compared to other 
molecular techniques. However, the drawback of RFLP method is it’s a low throughput 
method since most of the steps need to be performed manually. It’s the method adopted 
in laboratories handling fewer samples.  
Clinicians and researchers also use other DNA analysis methods that include whole-
exome sequencing (WES) to identify pathogenic single-nucleotide variants (SNVs). 
This is achieved by sequencing only the protein-coding portions of the β-globin gene 
followed by copy number variation analysis of the beta globin locus to determine 
normal vs. sickle mutation. These sequencing methods provide the most accurate and 
comprehensive report of the beta-globin gene. However, the cost involved is much 





2.2 SCD Diagnosis by using emerging Point-of-care (POC) methodologies: 
 
The idea behind recent methodologies is to make SCD screening accessible by adapting 
to technologies that are available at the POC even in the most developing nations. The 
emerging technologies consider the cost of a particular methodology, complexity of 
use, accessibility and availability of trained personnel. The emerging technologies in 
the past few years have thus been categorized into four groups: (a) paper-based 
hemoglobin solubility assays, (b) lateral flow immunoassays, (c) density-based 
separation, and (d) micro engineered electrophoresis. Each of these methodologies has 
been explained in detail below.  
2.21 Paper-based Hemoglobin Solubility Assay: 
The principle behind this technology is the insoluble property of hemoglobin and the 
filtration ability of paper. This assay uses a microfluidic paper-based device known as 
μPADs, to analyze the samples. In this way the HbS in the sample can be seen with our 
eyes. A drop of blood (~20μL) is mixed with hemoglobin solubility buffer in a 1:10 
ratio and then put onto a chromatography paper that is patterned (Fig. 2). Based on the 
different capillary action pattern of different hemoglobin types, various bloodstain 
patterns are observed for HbS that is polymerized and other hemoglobin types 
(Shevkoplyas et al. 2017). Screening can be achieved within 20 minutes and the method 
is 94.2% sensitive (see Table 1 below) (Yang et al. 2013). The advantage of this paper-
based is that it is cheaper compared to other methods, easy to interpret and sample 
preparation is very easy. Individual tests can be performed without the need to batch 
samples.  
The technique however suffers from few disadvantages. First, if the blood clots before 
adding to the μPAD, then the capillary action of the blood is lost, and the blood would 
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not be absorbed in the paper. The interpretation depends on naked eye detection and 
hence the assay is completely operator based and thus prone to error. To minimize error 
an automated image-processing algorithm can be paired with this assay. The assay 
cannot distinguish between the hemoglobin types HbSC and HbAS. Newborns have 
high percentage of HbF which may hinder the polymerization of HbS and thus this test 
has limited application in terms of newborn screening (Mulumba et al. 2015).  
 
Figure 2 Paper-based Hemoglobin Solubility Assay: The figure shows stepwise illustration of the above-mentioned 
assay (upper panel). The pattern and the color intensity profile are studied to determine the type of hemoglobin 
present in an individual (Shevkoplyas 
 
2.22 Lateral Flow Immunoassays: 
Lateral flow immunoassay also known as Sickle SCAN, can be used to detect HbA, 
HbS and HbC (Fig 3A). Different polyclonal antibodies are conjugated with colored 
nanoparticles and this combination is immobilized in a test strip on four different test 
lines, in which each line corresponds to a hemoglobin type (HbA, HbS, HbC, and 
Control). The control line ensures that no error has occurred during the procedure. Five 
microliter of sample blood is mixed with hemoglobin solubility buffer in 200:1 ratio 
and applied to the strip. The sample moves along the paper strip and once it reaches the 
lines corresponding antigen-antibody complexes are formed. Formation of a colored 
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line indicates the presence of the corresponding hemoglobin in the blood sample. The 
entire procedure takes only 2 minutes and has a sensitivity of ~99% (Kanter et al. 2015). 
A recent study reported the sensitivities of the different hemoglobin in the blood to be 
98.3%, 99.5% & 100% for HbA, HbS, and HbC respectively. As low as 2% of 
hemoglobin concentration was found to be sufficient to properly conduct the assay. 
This study also found out that presence of high percentage of HbF did not affect the 
detection of HbS or HbC (McGann et al. 2016). The specificity and sensitivity of this 
methodology are shown in the table 1 below. The above study also investigated the 
shelf-life of this device and found that the device properly functioned even after being 
stored at 37o C for 30 days. The assay has few disadvantages. The assay relies on visual 
confirmation that can sometimes lead to misinterpretation of actual result. The antibody 
conjugation with colored nanoparticle makes the device expensive due to increase in 
fabrication complexity. The presence of antibody requires the device to be ideally 
stored at low temperatures or under refrigeration.  
HemoTypeSC is a new type of lateral flow assay that uses monoclonal antibodies 
against HbA, HbS and HbC. This assay consists of the following parts: a) Sample pads 
laminated with fiberglass. b) A Nitrocellulose membrane with antibodies to different 
types of hemoglobin at four different locations of the membrane (antibodies 
corresponding to three hemoglobin and one control) and c) A cellulose wick (Fig. 3B). 
One microliter of blood is diluted to 1mL with distilled water followed by addition of 
15μL of this diluted blood to the sample pad. This is then immersed in a 150μL assay 
buffer solution containing red-colored colloidal gold nanoparticles and the solution is 
allowed to be absorbed in the strip for 10 minutes before taking the strip out of the 
solution.  The test strip is then visually detected for the line on the strip where the 
antibodies are deposited, which indicates the presence of the specific hemoglobin type. 
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It takes around 20 minutes to obtain result by this assay (Quinn et al .2016). The 
HemoTypeSC assay achieved 100% sensitivity and at the same time had a low 
operating cost. The assay was able to distinguish between HbAA, HbAS, HbAC, HbSS, 




Figure 3 Lateral Flow Immunoassay: (A) The sample is added in the application pad, which then moves via capillary 
action to the test lines conjugated with different polyclonal antibodies as shown. The blue line that appears notifies 
the type of hemoglobin present. 
2.23 Density-Based Separation: 
This technique uses the difference in cell densities to separate SCD cells from normal 
cells. SCD cells are relatively denser than the normal cells. Aqueous multiphase 
systems (AMPS) have been developed by Kumar et al. It consists of two or three-phase 




a sensitivity as high 90-91% and specificity ranging from 88-97% (Kumar et al. 2014). 
Five microliters of blood are mixed with aqueous polymeric solution and then loaded 
into capillary tubes (Fig. 4). The tubes are then centrifuged for 10 minutes that causes 
dense RBC of SCD patients to settle. This method has several limitations that include 
the higher cost due to inclusion of the centrifugation step. Centrifugation also makes it 
difficult to conduct this test at POC settings. Besides samples need to be run in batches 
increasing the turnaround time. Density based separation method cannot differentiate 
between HbAA and HbAS. Also, newborn screening is not possible with this method 
due to the presence of high % of HbF that restricts the occurrence of dense RBC. Other 
factors like medication, health conditions, treatment processes and genetic factors affect 
the density of RBC and hence the outcome of test result of this assay (see Table 1 
below).  
Figure 4 The figure shows the different outcome of the density-based assay. The sample blood moves through the 
different phases i.e. top , middle, and bottom  and then accumulates at the interphases depending on the type of 
hemoglobin present (Kumar et al. 2014) 
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2.24 Micro engineered Electrophoresis: 
Micro engineered electrophoresis (HemeChip) is a SCD screening method recently 
developed and can be used to differentiate between HbA, HbA2, HbS, HbF and HbC. 
The HemeChip device consists of a cellulose acetate paper for electrophoresis that is 
housed in a microfabricated Polymethyl Methacrylate (PMMA) chamber. An electric 
field is applied, and the types of hemoglobin are separated. An application software that 
can be downloaded and used in the mobile phone for image processing purpose at the 
POC has also been developed (Fig. 5). This software is used to quantitate the 
hemoglobin amount in the HemeChip (Ung et al. 2015).   
Less than 5μL of blood is first mixed with deionized (DI) water to lyse the RBC and 
release Hb content into the solution. Less than 1μL of this is then stamped onto the 
cellulose acetate paper and an electric field is applied that causes the hemoglobin types 
to travel different distances across the paper strip. The result can be achieved in as little 
time as 10 minutes with high sensitivity and specificity among the different hemoglobin 
types. It is a low-cost assay that has relatively good accuracy and takes very less time 
to get result. This methodology can be compared in terms of detection and 
quantification quality with standard HPLC assay and electrophoresis screening 
methods used in laboratories. The inclusion of mobile devices to analyze the result also 
makes this device quite practical in terms of its usage at the POC. This device requires 
a very low power supply, which can be easily substituted with a rechargeable battery 
for field applications. However, detection of high percentage of HbF in newborns that 
usually overshadows other Hb types is still a challenge (see Table 1 below).  
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Figure 5 A) The HemeChip with blood sample being separated into respective bands different hemoglobin type B) 
Graph showing Sensitivity and specificity C) Mobile Software for image processing and quantification of HemeChip 
results at the POC (Ung et al. 2015). 
 
Table 1 Summary of methodology for screening SCD at Point of Care Testing. 













Easy to use, no 
batching required 
Cannot distinguish 
HbSC and HbAS, 
Blood clotting issue; 
result interpretation 












Easy to use, result 
can have obtained 
rapidly, no other 
additional 
Cannot quantitate Hb; 
result interpretation 
affected by human 
error 
$5 NA 2 mins 99% 99% McGan












No support for 
quantification; result 
interpretation affected 
by human error 
$0.25 NA 20 mins 100% 100% Quinn 





rapidly, Simple to 
operate 
Bulky centrifuge 
requirement makes this 
less practical to be used 
at POC; Batching 
needed to run 
centrifuge; cannot 
differentiate between 
HbAA and HbAS; high 
HbF levels can give 
inaccurate results; 
health and treatment 
conditions can alter 
RBC density 
$0.5 $150-1600 10 mins 90-91% 88-97% Kumar 






Easy to use, low 
cost, robustness, 





assays, can be 
annexed with a 
mobile device;  
High HbF 
concentration in 
newborns can make it 
difficult to interpret the 
result 
$0.9 $500 for 
automated 
detection 






3. Discussion and Conclusions: 
 
Proper screening and early diagnosis of SCD individuals is vital to their management 
and treatment. Improper screening or a delay results in higher mortality rates among 
SCD patients. Several SCD screening techniques were developed in the early 1970s. 
Unfortunately, many such methodologies proved to be unreliable since they gave false 
positive or negative results that led to wrong treatment and confusion. In order to 
standardize laboratory techniques and interpretation for SCD screening a 
Hemoglobinopathy Reference Laboratory (HRL) was created at the Centers of Disease 
Control (CDC) (Naik et al. 2015).  
This review focused on the different methodologies that are currently used to screen 
SCD individuals that include both newborns and adults. The most common screening 
methodologies currently used comprise of sickle solubility testing, electrophoresis, 
HPLC, CZE and IEF. Sickle solubility-based screening assays usually have lower cost 
and they are based on the principle of insolubility of HbS in a reducing agent that causes 
turbidity due to lysis of HbS- containing RBC in solution. The solubility test however 
cannot differentiate between SCD and SCT individuals and gives false negative result 
in newborns with higher HbF content. Hence additional tests that include hemoglobin 
electrophoresis, HPLC and IEF are also used that serve the purpose of either being 
primary identification of sickle hemoglobin types or as confirmatory tests. These 
techniques can provide quantification of hemoglobin and clearly differentiate between 
SCT and SCD individuals. Hemoglobin electrophoresis method is based on the 
principles of gel electrophoresis and is an inexpensive method that separates types of 
hemoglobin present in the blood based on their relative size and charge.  
IEF is based on the principle that the net charge in the proteins varies based upon the 
surrounding pH and at their respective isoelectric point (pI) all proteins carry zero 
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charge. Hemoglobin molecules present in the blood samples are thus run in a gel having 
pH gradient under an electric field and they stop as they reach their respective pI points. 
IEF methodology has relatively low cost and has high throughput abilities and thus is 
the assay–of-choice in many clinical laboratories. In this context a pilot study conducted 
in Tunisia, Africa has been mentioned here that uses a low cost SCD screening 
technique by collecting blood samples on blotting paper printed in a common office 
printer and then analyzing the samples in a laboratory prepared gel for IEF assay (Hajer 
et al .2012). 
HPLC although being an expensive method for hemoglobinopathy screening is used in 
many clinical laboratories across developed nations for its accuracy in detection and 
less time to get result.  
An alternative methodology for screening SCD individuals is LC-MS/MS, which is 
able to detect Hb peptides following digestion of blood spots with trypsin. This is also 
an extremely accurate and fast method that can be applied for population screening for 
identification of clinically important globin mutations. 
SCD screening can also be achieved by DNA analysis, one of the methodology in this 
category include RFLP assay, in which β-globin gene is first PCR amplified and then 
cut with the restriction enzyme DdeI. Absence of this restriction site indicates the 
presence of mutated β-globin gene since the point mutation eliminates the above 
restriction site. Whole exome genome sequencing (WES) to look for SNVs in the β-
globin gene is also currently followed by several laboratories although sequencing is 
an expensive technology and only developed nations can afford it. 
The review also explains the emerging POC methodologies that are developed 
considering the cost factor at a certain location, trained technicians available and 
accessibility. Four such emerging methodologies have been discussed here that are as 
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follows, a) paper-based hemoglobin assays, b) lateral flow immunoassays, c) density-
based separation, and d) micro engineered electrophoresis (HemeChip). 
The paper-based hemoglobin assay takes utilizes capillary action of blood sample when 
applied to a paper-based device called μPADs that causes different hemoglobin types 
of form unique patterns that can be easily distinguished from one another.  
The lateral flow immunoassay comprises of a test strip that has polyclonal antibodies 
against different hemoglobin types conjugated with colored nanoparticles. An antigen-
antibody complex is formed between respective hemoglobins once the blood sample 
reaches the lines in the strip.  
Density-based separation has an AMPS comprising of two and three phases that uses 
cell density measurements to detect RBC. Blood samples are centrifuged in capillary 
tubes and SCD cells that are of higher density settle at the lowest interphase.  
The micro engineered electrophoresis (HemeChip) consists of a cellulose acetate paper 
housed inside a PMMA chamber where sample blood electrophoresis is conducted to 
separate different hemoglobin types. A mobile-based application software can be used 
that is compatible with this assay to process image.  
Most of these emerging methodologies are able to distinguish between HbA, HbA2, 
HbS, HbF and HbF hemoglobin types. These emerging methodologies are based on 
resources that are easily available at the POC of even economically challenged nations.  
The advantages and disadvantages of each methodology for screening of SCD have 
been discussed in this review. However, considering every factor that includes overall 
cost, practicality of using an assay in both developed and developing nations, available 
resources to perform the test, sensitivity, specificity, different Hb variants that can be 
identified with certainty, the methodology-of-choice would be Lateral Flow 
immunoassay (Sickle SCAN and HemoTypeSC). This methodology is categorized as a 
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POC assay because of its low cost and easy-of-use even in remote areas of developing 
nations. As can be seen in Table 1, the lateral flow assay has both sensitivity and 
specificity ranging between 99-100%.  The cost of running the assay varies from $0.25-
$5, which is low compared to more expensive assays like HPLC and WES. A recent 
study has been conducted in order to select the best methodology based on the low cost 
of use, portability, easy-to-use diagnostic tests especially in resource-poor countries 
(Nwegbu et al. 2017).  In this study the performance characteristics of Lateral flow 
assay (Sickle SCAN) was compared with cellulose acetate electrophoresis (CAE) and 
high-performance liquid chromatography (HPLC) by evaluating several subjects for 
HbSS, HbSC and HbAS.  The SickleSCAN™ showed diagnostic sensitivity, specificity 
and test efficiency of 100.0, 98.2 and 98.2%, respectively for sickle cell disease (Hb SS 
and Hb SC) that was comparable to the other two methods but at a much lower cost and 
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